Related Experiment Video
Updated: Oct 19, 2025

Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Safety of Intravenous Autologous Bone Marrow-Derived Mesenchymal Cell Transplantation in 5 Patients With Reduced Left
Yukihito Sato1, Takashi Kuragaichi1, Shunsuke Saga1
1Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center Amagasaki Japan.
Abstract:
Although intracardiac injection or intracoronary delivery of mesenchymal stem cells (MSCs) has been reported, there have been few studies on the intravenous injection of MSCs, particularly in Japan. Five patients with left ventricular ejection fraction (LVEF) ≤45% received 1.0×108 MSCs intravenously. The procedure did not induce significant changes in vital signs. One patient had an elevated body temperature after 1 day, but recovered spontaneously. Laboratory tests remained normal for 1 month after cell delivery. Computed tomography was performed after 1-2 years, and there was no evidence of malignancy. In this pilot study of patients with reduced LVEF, intravenous MSC delivery had no adverse effects.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Mesenchymal Stem Cells

